Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Phase I study of CC-90010, a reversible, oral BET inhibitor in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)

Date

03 Mar 2020

Session

Proffered Papers 2: Individual targets

Presenters

Victor Moreno

Citation

Annals of Oncology (2020) 31 (suppl_1): S8-S10. 10.1016/annonc/annonc82

Authors

V. Moreno1, I. Braña2, J.M. Sepulveda Sanchez3, M. Vieito Villar2, T. Hernández Guerrero1, B. Doger4, O. Saavedra5, A. Pinto6, C. Carlo Stella7, A. Italiano8, J. Michot9, G. Musuraca10, R. Sarmiento11, J. De Alvaro11, M. Zuraek12, T. Sánchez-Pérez11, I. Aronchik12, E. Filvaroff12, B. Hanna12, Z. Nikolova11

Author affiliations

  • 1 START Madrid-FJD, Hospital Universitario Fundación Jimenez Diaz, 28040 - Madrid/ES
  • 2 Hospital Universitari Vall d’Hebron, 08035 - Barcelona/ES
  • 3 Hospital Universitario 12 de Octubre, 28041 - Madrid/ES
  • 4 START Madrid-FJD, Hospital Universitario Fundación Jimenez Diaz, Madrid/ES
  • 5 Hospital Universitari Vall d’Hebron, Barcelona/ES
  • 6 Istituto Nazionale Tumori IRCSS Fondazione Pascale, Naples/IT
  • 7 Humanitas Cancer Center, Humanitas Clinical and Research Center, Milan/IT
  • 8 Institut Bergonie Centre Regional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest, 33076 - Bordeaux/FR
  • 9 Department Of Hematology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 10 Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori (IRST), Meldola/IT
  • 11 Celgene, A Bristol-Myers Squibb Company, Summit/US
  • 12 Bristol-Myers Squibb, Summit/US
More

Resources

Bromodomain and extra-terminal (BET) proteins are epigenetic readers that regulate expression of genes involved in oncogenesis. CC-90010 is a potent BET inhibitor that showed preliminary antitumor activity in pts with advanced malignancies.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings